Please enter both email and password to log in
You need to upgrade your Flash Player
|
You need to upgrade your Flash Player to view this content.
What's New?
New CME-certified case study!
The Role of Nonpharmacologic and Lipid-Lowering Therapies in a Patient With Low Framingham-Assessed Cardiovascular Risk. M. Dominique Ashen, PhD, CRNP, and CCMD Faculty Member Roger S. Blumenthal, MD, explore nonpharmacologic and lipid-lowering treatments for a patient with evidence of increased cardiovascular risk beyond that suggested by Framingham Risk Scoring. Earn 0.75 AMA PRA Category 1 Credit™ and access to an anthology of CCMD slides instantly!
|
OnsiteInsight® from AHA Scientific Sessions 2008!
This issue of OnsiteInsight® highlights clinical-trial results and scientific sessions focusing on issues in the management of atherosclerosis from the American Heart Association Scientific Sessions 2008 in New Orleans! Also featured: expert commentary from CCMD Education Council Member JoAnne M. Foody, MD.
|
New Slides on JUPITER data
Check out our latest slides featuring an NHANES extrapolation of the population meeting JUPITER study eligibility.
|
Daily Updates from ADA 2009
Read daily summaries and expert insights on data presented at the American Diabetes Association 69th Scientific Session in New Orleans.
|
In the News
Determining Success Or Failure In Cholesterol-Controlling Drugs
May 16, 2009 -- Researchers at the University of California, San Diego have discovered that a complex network of interactions between drugs and the proteins with which they bind can explain adverse drug effects. Their findings suggest that adverse drug effects might be minimized by using single or multiple drug therapies in order to fine-tune multiple off-target interactions.
|
FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
Jul 03, 2009 -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq(R) is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
|
|
|
|
|
CCMD Co-Chairmen
|
Education Council
George L. Bakris, MD
|
Elizabeth Barrett-Connor, MD
|
Keith C. Ferdinand, MD
|
JoAnne M. Foody, MD
|
Peter Ganz, MD
|
Philip B. Gorelick, MD, MPH
|
Scott M. Grundy, MD, PhD
|
Steven M. Haffner, MD
|
Ronald M. Krauss, MD
|
John C. LaRosa, MD
|
Peter Libby, MD
|
Thomas A. Pearson, MD, MPH, PhD
|
|
|